title: The impact of common classes of topical antiglaucoma medications on central corneal thickness--own observations.
abstract: OBJECTIVE
  To investigate the influence of common classes of topical antiglaucoma medications used either in monotherapy or combined therapy on CCT.
  
  
  METHODS
  In a retrospective study 487 eyes from consecutive 260 patients (148 F/112 M) with open angle glaucoma were examined. Depending on the topical treatment they were classified into 7 groups: A/PGA (n=212), B/BB (n= 54), C/CAI (n=36), D/PGA + CAI (n=25) E/PGA + BB (n=23) F/BB + CAI (n=54), G/ non-treated (n=83). The CCT was measured using ultrasound pachymetry Tomey AL-2000. The central corneal power was measured with the Topcon keratometer. ANOVA analyses were used for statistical analysis.
  
  
  RESULTS
  There were no statistically significant differences between CCT of all groups (F = 1.06, p = 0.3931); the lowest values were in the eyes treated with PGA + BB (535.9 microm SD 31.4) and the highest in the eyes treated with PGA + CAI (571.3 microm SD 46.3). The Mean CCT in group A was 550.4 microm (SD 40.8), group B 552.5 microm (SD 34.7), group C 562.6 microm (SD 40.2), group D 571.3 microm (SD 46.3), group E 535.9 microm (SD 31.4), group F 559.5 microm (SD 32.5), group F 557.5 microm (SD 42.2). There were no statistically significant differences between CCT of eyes treated with different PGA. The highest CCT was found in the eyes treated with bimatoprost (554.4 microm SD 46.0) and the lowest in the eyes treated with latanoprost (546.4 microm SD 37.7).
  
  
  CONCLUSIONS
  In this study CCT appears not to differ in eyes treated with different classes of antiglaucoma medications either in monotherapy or combined therapy. CCT appears not to differ in eyes treated with different prostaglandin and prostamide anal logs. CCT of treated glaucoma eyes does not differ from CCT of untreated glaucoma eyes.
authors.affiliation: Department of Ophthalmology, Military Health Service Institute, Warsaw. joanna.wierzbowska@gmail.com
authors.forename: Joanna
authors.initials: J
authors.lastname: Wierzbowska
authors.forename: Anita
authors.initials: A
authors.lastname: Łagocka
authors.forename: Anna
authors.initials: A
authors.lastname: Siemiatkowska
authors.forename: Jacek
authors.initials: J
authors.lastname: Robaszkiewicz
authors.forename: Andrzej
authors.initials: A
authors.lastname: Stankiewicz
authors.forename: Janusz
authors.initials: J
authors.lastname: Sierdziński
mesh_terms: D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D003315:Cornea / Q000187:drug effects* / Q000473:pathology*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage* / Q000009:adverse effects*; D011453:Prostaglandins / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002257:Carbonic Anhydrase Inhibitors; D009883:Ophthalmic Solutions; D011453:Prostaglandins